OMEROS CORP Payments of Stock Issuance Costs
OMEROS CORP (OMER) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-04-01
- OMEROS CORP payments of stock issuance costs for the quarter ending 2021-12-31 was $0.00.
- OMEROS CORP payments of stock issuance costs for the quarter ending 2021-09-30 was $0.00.
- OMEROS CORP payments of stock issuance costs for the quarter ending 2021-06-30 was $0.00.
- OMEROS CORP payments of stock issuance costs for the quarter ending 2021-03-31 was $241.00K.
- OMEROS CORP payments of stock issuance costs for fiscal 2023 was $0.00.
- OMEROS CORP payments of stock issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- OMEROS CORP payments of stock issuance costs for fiscal 2021 was $241.00K.
- OMEROS CORP payments of stock issuance costs for fiscal 2009 was $6.39M.
| Period end | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 204 month | Payments of Stock Issuance Costs 207 month |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-04-01 | ||||||
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $241.00K 10-K · filed 2024-04-01 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $241.00K 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $241.00K 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | $241.00K 10-Q · filed 2022-05-10 | ||||||
| 2015-02-28 | $4.90M 10-K · filed 2018-03-01 | ||||||
| 2014-09-30 | $2.50M 10-Q · filed 2014-11-10 | ||||||
| 2014-06-30 | $2.50M 10-Q · filed 2014-08-11 | $5.00M derived: sum of 2 quarters · filed 2015-05-11 | |||||
| 2014-03-31 | $2.50M 10-K · filed 2017-03-16 | $2.50M 10-Q · filed 2015-05-11 | |||||
| 2013-05-31 | $39.00K 10-K · filed 2016-03-15 | ||||||
| 2012-07-31 | $2.20M 10-K · filed 2015-03-16 | ||||||
| 2011-09-30 | $0.00 derived: 10-Q 207 month − 10-Q 204 month · filed 2011-11-08 | $6.39M 10-Q · filed 2011-11-08 | |||||
| 2011-06-30 | $6.39M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $6.39M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |